Listing & Compliance Notices

SOLIGENIX, INC. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)).

“April 6, 2023, Nasdaq granted the Company’s request for an extension of the deadline by which it must regain compliance with the Shareholders’ Equity Requirement from March 31, 2023 to May 15, 2023. The Company is working diligently to satisfy, and intends to regain compliance with, the Shareholders’ Equity Requirement; however, there can be no assurance that the Company will be able to do so prior to the deadline established by Nasdaq, or at all, or that the Company’s common stock will remain listed on The Nasdaq Capital Market. ​ Safe Harbor for Forward-Looking Statements ​ Certain statement”

ALSP Orchid Acquisition Corp I received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“April 5, 2023, ALSP Orchid Acquisition Corporation I (the “Company”) received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was deficient in meeting the requirements of Listing Rule 5450(b)(2)(A), which requires the listed securities of the Company to maintain a minimum Market Value of Listed Securities (“MVLS”) of $50,000,000. The Letter is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on Nasdaq. In accordance with Nasdaq Listing Rule 5810(c)(3)(C)”

Opy Acquisition Corp. I received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5810(c)(3)(C)).

“April 3, 2023, OPY Acquisition Corp. I (the “Company”) received a letter (the “MVLS Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days prior to the date of the MVLS Notice, the Company’s Minimum Market Value of Listed Securities (“MVLS”) was less than $50.0 million, which does not meet the requirement for continued listing on The Nasdaq Global Market, as required by Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(C)”

SYNTEC OPTICS HOLDINGS, INC. received a nasdaq deficiency notice notice regarding market value.

“April 4, 2023 and informed NASDAQ that the Company had 3,791,677 Class B shares available for voluntary conversion to 3,791,677 Class A shares to achieve compliance. On April 6, 2023, NASDAQ indicated the Company should trade for 10 calendar days at a minimum of $50,000,000 Market Value of Listed Securities after conversion to comply with the Listing Rules. On April 4, 2023 the Company reported to NASDAQ that the Company does not meet the required listed securities to maintain a minimum Market Value of Publicly Held Shares (MVPHS) of $15,000,000. On the same day, NASDAQ provided a letter of no”

SYNTEC OPTICS HOLDINGS, INC. received a nasdaq deficiency notice notice regarding market value.

“April 3, 2023, OmniLit Acquisition Corp. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market (“NASDAQ”) indicating that the Company required to maintain a minimum of $50,000,000 Market Value of Listed Securities (MVLS) for continued listing on Nasdaq Global Market and did not comply with Listing Rules. Following receipt of the Notice, the Company promptly responded on April 4, 2023 and informed NASDAQ that the Company had 3,791,677 Class B shares available for voluntary conversion to 3,791,677 Class A shares to achieve”

EUDA Health Holdings Ltd received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“April 5, 2023 due to the Company’s non-compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule” ) as a result of the Company’s failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “ Form 10-K ”). The Rule requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the “ SEC ”). The Notice states that the Company has 60 calendar days to submit to Nasdaq a plan to regain compliance with the Nasdaq Listing Rules. If Nasdaq accepts the Company’s plan, then Nasdaq may grant the Comp”

Virgin Orbit Holdings, Inc. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1, 5250(c)(1)).

“April 4, 2023, Virgin Orbit Holdings, Inc. (the “Company”) was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that Nasdaq had determined to commence proceedings to delist the Company’s common stock, par value $0.0001 par per share (the “Common Stock”), and the Company’s warrants to purchase Common Stock (the “Warrants”) from Nasdaq. Nasdaq reached its decision that the Company is no longer suitable for listing pursuant to Nasdaq Listing Rules 5101, 5110(b), and IM‐5101-1 as a result of the Company’s commencement of voluntary proceedings under Chapte”

Owlet, Inc. received a nyse deficiency notice notice regarding market value (rules 802.01B).

“April 4, 2023, Owlet, Inc. (the “Company”) received written notice (the “NYSE Notification”) from the New York Stock Exchange (the “NYSE”) that the Company is not in compliance with Section 802.01B of the NYSE Listed Company Manual because the average global market capitalization of the Company over a consecutive 30 trading-day period and, at the same time, the Company’s last reported stockholders’ equity were each less than $50 million. The Company plans to notify the NYSE that it intends to submit a plan to cure the deficiency and to return to compliance with the NYSE continued listing stand”

Sports Entertainment Gaming Global Corp received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“April 4, 2023, the Company received an additional notice (the “ Notice ”) from Nasdaq indicating that as a result of the fact that the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 has not been filed, Nasdaq did not receive the Annual Report, and it does not comply with Nasdaq’s filing requirements set forth in Listing Rule 5250(c)(1), this matter serves as an additional basis for delisting the Company’s securities from The Nasdaq Stock Market. As previously disclosed, the Company has requested a hearing to appeal Nasdaq’s delisting determination. At the panel heari”

Super League Enterprise, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“April 4, 2023, Super League Gaming, Inc. (the “ Company ”) received a letter (the “ Extension Notice ”) from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC (“ Nasdaq ”) notifying the Company that Nasdaq has granted the Company a 180-day extension, or until October 2, 2023 (the “ Extension Period ”), to regain compliance with the requirement for the Company’s common stock, par value $0.001 per share (“ Common Stock ”), to maintain a minimum bid price of $1.00 per share for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “ Min”

PLx Pharma Winddown Corp. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“isting requirement of The Nasdaq Capital Market based on its burn rate of approximately $4.25 million per month. The April Notice also stated that the Company had not yet filed its Form 10-K for the period ended December 31, 2022, meaning that the Company no longer complies with Nasdaq Listing Rule 5250(c)(1). As a result, unless the Company requests an appeal of Nasdaq’s determination pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series, trading of the Company’s common stock will be suspended from The Nasdaq Capital Market at the opening of business on April 13, 2023, a”

Goldman Sachs ETF Trust received a other deficiency notice notice regarding other.

“April 5, 2023, the compliance staff (the “Staff”) of Cboe BZX Exchange, Inc. (“Cboe”) provided written notice to Goldman Sachs ETF Trust (the “Trust”) that it is not in compliance with the continued listing standard set forth in Exchange Rule 14.11(l)(4)(B)(i)(c) of Cboe with respect to one of its series, the Goldman Sachs ActiveBeta ® Paris-Aligned Climate U.S. Large Cap Equity ETF (the “Fund”). Exchange Rule 14.11(l)(4)(B)(i)(c) requires that, in order to comply with Cboe continued listing standards, a listed company must maintain no fewer than 50 beneficial holders of series of ETF Shares f”

VAALCO ENERGY INC /DE/ received a nyse noncompliance notice notice regarding late filing (rules 802.01E).

“April 3, 2023, VAALCO Energy, Inc. (the “Company”) received a notice from The New York Stock Exchange (the “NYSE”) that the Company was not in compliance with the continued listing requirements under the timely filing criteria established in Section 802.01E of the NYSE Listed Company Manual, because the Company did not timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (“Form 10-K”) with the Securities and Exchange Commission (the “SEC”) on or prior to the due date thereof or by the extended filing due date provided by Rule 12b-25. The NYSE informed the Comp”

CERO THERAPEUTICS HOLDINGS, INC. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“April 3, 2023, Phoenix Biotech Acquisition Corp., a Delaware corporation (the “ Company ”), received a letter (the “ Letter ”) from the staff at The Nasdaq Global Market (“ Nasdaq ”) notifying the Company that, for the 30 consecutive trading days prior to the date of the Letter, the Company’s common stock had traded at a value below the minimum $50,000,000 “Market Value of Listed Securities” (“ MVLS ”) requirement set forth in Nasdaq Listing Rule 5450(b)(2)(A), which is required for continued listing of the Company’s common stock on Nasdaq. The Letter is only a notification of deficiency, not”

Mountain Crest Acquisition Corp. V received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5810(c)(3)(A)).

“ved a notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), stating that the Company’s listed securities failed to comply with the $50,000,000 market value of listed securities (“MVLS”) requirement for continued listing on The Nasdaq Global Market in accordance with Nasdaq Listing Rule 5450(b)(2)(A) based upon the Company’s MVLS for the 30 consecutive business days prior to the date of the Notice. The Notice has no immediate effect on the listing of the Company’s securities on Nasdaq and in accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided a period o”

Tevogen Bio Holdings Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“April 4, 2023, Semper Paratus Acquisition Corporation (the “Company”) received a written notice (the “Letter”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company was not in compliance with Listing Rule 5450(b)(2)(A), requiring the Company to maintain a Market Value of Listed Securities (“MVLS”) of $50,000,000 for the continued listing of its securities on The Nasdaq Global Market. The Letter is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securi”

KORE Group Holdings, Inc. received a nyse deficiency notice notice regarding late filing (rules 802.01E).

“April 3, 2023, the Company received a notice from the New York Stock Exchange (the “NYSE”) indicating that the Company is not in compliance with the NYSE’s continued listing requirements under the timely filing criteria outlined in Section 802.01E of the NYSE Listed Company Manual as a result of the Company’s failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “2022 Form 10-K”) with the Securities and Exchange Commission (the “SEC”). The NYSE informed the Company that, under the NYSE’s rules, the Company will have six months from the due date”

Mercato Partners Acquisition Corp received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“April 5, 2023, Mercato Partners Acquisition Corporation, a Delaware company (the “Company”) received a letter (the “Letter”) from the staff at The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the 30 consecutive trading days prior to the date of the Letter, the Company’s common stock had traded at a value below the minimum $50,000,000 “Market Value of Listed Securities” (“MVLS”) requirement set forth in Nasdaq Listing Rule 5450(b)(2)(A), which is required for continued listing of the Company’s common stock on The Nasdaq Global Market. The Letter is only a notification of d”

Newcourt Acquisition Corp received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“April 3, 2023, Newcourt Acquisition Corp (the “Company”) received a written notice (the “Letter”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company was not in compliance with Listing Rule 5450(b)(2)(A), requiring the Company to maintain a Market Value of Listed Securities (“MVLS”) of $50,000,000 for the continued listing of its securities on The Nasdaq Global Market. The Letter is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on Nasda”

Intelligent Medicine Acquisition Corp. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(C)).

“April 5, 2023, Intelligent Medicine Acquisition Corp. (the “Company”) received a letter (the “MVPHS Letter”) from the Listing Qualifications division (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) Company’s listed securities failed to comply with the $15 million market value of publicly held shares (“Market Value of Publicly Held Shares”) requirement for continued listing on the Nasdaq Global Market in accordance with Nasdaq Listing Rule 5450(b)(2)(C) based upon the Company’s Market Value of Publicly Held Shares for the 30 consecutive business days prior to the date of the MVPHS Notic”

Landcadia Holdings IV, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“April 3, 2023, Landcadia Holdings IV, Inc. (the “Company”) received a letter from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the Company’s minimum Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “Market Value Standard”). The notice has no immediate effect on the listing of the Company’s common stock, and the Company’s common stock continues to trade”

Spectaire Holdings Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“April 3, 2023, Perception Capital Corp. II (the “ Company ”) received a letter (the “ Letter ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) that, for the previous 30 consecutive business days, the Market Value of Listed Securities (“ MVLS ”) for the Class A ordinary shares of the Company, par value $0.0001 per share (“ Class A Ordinary Shares ”), was below the $50 million minimum MVLS requirement for continued listing on The Nasdaq Global Market under Nasdaq Listing Rule 5450(b)(2)(A) (the “ MVLS Rule ”). The Letter is only a notification of deficienc”

Better Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“of at least $2,500,000 (the “Stockholders’ Equity Requirement”). The Company’s Annual Report on Form 10-K for the year ended December 31, 2022, reported stockholders’ deficit of $899,000, which is below the Stockholders’ Equity Requirement for continued listing on the Nasdaq Capital Market. The Letter further noted that as of its date, the Company did not have a”

Hyzon Motors Inc. received a nasdaq hearing update notice regarding late filing (rules 5250(c)(1)).

“The Nasdaq Capital Market until May 15, 2023 was granted subject to the condition that on or before May 15, 2023, the Company shall have filed with the Securities and Exchange Commission all delinquent reports, in compliance with the Periodic Filing Rule. On April 3, 2023, the Company filed a Form 12b-25 to report that its Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Form 10-K”) would not be filed within the prescribed time period. On April 6, 2023, the Company received an additional Staff Determination (the “Additional Staff Determination”) from the Staff notify”

T Stamp Inc received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“(the “ Stockholders’ Equity Requirement ”). The Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed March 30, 2023 reported stockholders’ equity of $625,144, which is below the Stockholders’ Equity Requirement for continued listing on the Nasdaq Capital Market. As of the date of this Current Report on Form 8-K, the Company does not”

Quoin Pharmaceuticals, Ltd. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“April 5, 2023, Quoin Pharmaceuticals Ltd. (the “Company”) received a letter from the Listing Qualifications staff of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that the closing bid price per American Depositary Share (“ADS”) representing 5,000 ordinary shares of the Company was below the required minimum of $1.00 for a period of 30 consecutive business days and that the Company did not meet the minimum bid price requirements set forth in Nasdaq Rule 5550(a)(2). Pursuant to Nasdaq Rule 5810(c)(3)(A), the Company has a period of one hundred eighty (180) calendar days, or until”

Axcella Health Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(C), 5450(b)(2)(A)).

“April 3, 2023, Axcella Health Inc., (the “Company”) received written notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that (i) the Company was not in compliance with the requirement of a minimum Market Value of Publicly Held Shares (“MVPHS”) of $15,000,000 for continued listing on the Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(b)(2)(C); and (ii) the Company was not in compliance with the requirement of a minimum Market Value of Listed Securities (“MVLS”) of $50,000,000, as set forth in Nasdaq Listing Rule 5450(b)(2)(A”

Nemaura Medical Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).

“April 7, 2023, the Company received written notice (the “Bid Price Notice”) from the Nasdaq Staff indicating that the Company is not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Capital Market under the symbol “NMRD,” and the Company is currently monitoring the closing bid price of its common stock and evaluating its alternatives, if appropriate, to resolve th”

Nemaura Medical Inc. received a nasdaq noncompliance notice notice regarding market value (rules 5550(b)(2)).

“April 3, 2023, Nemaura Medical Inc. (the “Company”) received a written notice (the “MVLS Notice”) from the Nasdaq Listing Qualification Department (the “Nasdaq Staff”) indicating that the Company is not in compliance with the $35 million minimum market value of listed securities requirement set forth in Nasdaq Listing Rule 5550(b)(2) for continued listing on the Nasdaq Capital Market. The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Capital Market under the symbol “NMRD,” and the Company is currently monitoring the”

BIORA THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding other (rules 5450(b)).

“April 4, 2023, Biora Therapeutics, Inc. (the “ Company ”) received formal notice from the Listing Qualifications Staff (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Company no longer satisfies the $50 million in total assets and $50 million in total revenue requirement for continued listing on The Nasdaq Global Market or the alternative criteria under Nasdaq Listing Rule 5450(b) (the “ Rule ”). The Staff’s notice has no immediate effect on the listing of the Company’s common stock, which the Company expects will continue to trade on Nasdaq in the normal course”

Beeline Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“June 3, 2022 notifying the Company that the bid price for the Company’s common stock for the prior thirty consecutive trading days had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). On December 1, 2022, the Company received written notification from the Staff granting its request for a 180-day extension to regain compliance with the Bid Price Requirement. Eastside Distilling now has until May 30, 2023 to meet the requirement. If at any time prior to May 30, 2023, the bid”

Beeline Holdings, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“April 5, 2023, Eastside Distilling, Inc. received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying Eastside Distilling that, the Company’s stockholders’ equity as reported in its Annual Report on Form 10-K for the period ending December 31, 2022 (the “Form 10-K”), did not satisfy the continued listing requirement under Nasdaq Listing Rule 5550(b)(1) (the “Listing Rule”) for the Nasdaq Capital Market, which requires that a listed company’s stockholders’ equity be at least $2.5 million. As reported on its Form 10-K, the”

RBB Bancorp received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“April 3, 2023, RBB Bancorp (the “Company”) received a notice (the “Notice”) from The NASDAQ Stock Market (“Nasdaq”) stating that because the Company has not yet filed its Annual Report on Form 10-K for the year ended December 31, 2022 (the “Form 10-K”), the Company is no longer in compliance with Nasdaq Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the “SEC”). The Company was unable to file the Form 10-K, without unreasonable effort and expense, as the Company”

Molecular Templates, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(2)).

“April 4, 2023, Molecular Templates, Inc. (the “Company”) received an additional notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company no longer satisfied the $2.5 million minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market, as required by Nasdaq Listing Rule 5550(b)(2) (the “Equity Requirement”), which could serve as an additional basis for the delisting of the Company’s securities from Nasdaq. The Company plans to present its plan to evidence compliance with the Equity Requirement along with i”

INFINITY PHARMACEUTICALS, INC. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5450(b)(3)(A)).

“April 4, 2023, Infinity Pharmaceuticals, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5450(b)(2)(A) (the “Minimum MVLS Requirement”) for continued listing on the Nasdaq Global Select Market, as the market value of the Company’s listed securities was less than $50,000,000 for the previous 30 consecutive business days. The Staff also noted in its letter that the Company is not in compli”

URBAN ONE, INC. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“April 7, 2023, Urban One, Inc. (the “Company”), issued a press release announcing that it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with requirements of Nasdaq Listing Rule 5250(c)(1) as a result of not having timely filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “2022 Form 10-K”), with the Securities and Exchange Commission (“SEC”). This notification has no immediate effect on the listing of the Company’s common stock on the NASDAQ. However, i”

TUPPERWARE BRANDS CORP received a nyse noncompliance notice notice regarding late filing (rules 802.01E).

“April 3, 2023, Tupperware Brands Corporation (the “Company”) received a notice from the New York Stock Exchange (the “NYSE”) indicating the Company is not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2022 (the “Form 10-K”) with the Securities and Exchange Commission (the “SEC”). The NYSE informed the Company that, under NYSE rules, the Company has six months from the Form 10-K due date to regain compliance with the NYSE listing standards by filing the Form 10-K with”

VSEE HEALTH, INC. received a nasdaq deficiency notice notice regarding market value (rules 5450, 5810).

“March 31, 2023, Digital Health Acquisition Corp., a Delaware corporation (the “Company”), received a letter (the “Letter”) from the staff at The Nasdaq Global Market (“Nasdaq Global”) notifying the Company that for the 30 consecutive trading days prior to the date of the Letter, the Company’s securities listed on Nasdaq Global (including the Common Stock, Units and Warrants) (the “Securities”) had traded at a value below the minimum $50,000,000 “Market Value of Listed Securities” (“MVLS”) requirement set forth in Nasdaq Listing Rule 5450(b)(2)(A), which is required for continued listing of the”

Gardiner Healthcare Acquisitions Corp. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“March 31, 2023, Gardiner Healthcare Acquisitions Corp., a Delaware company (the “ Company ”) received a letter (the “ Letter ”) from the staff at The Nasdaq Global Market (“ Nasdaq ”) notifying the Company that, for the 30 consecutive trading days prior to the date of the Letter, the Company’s common stock, par value $0.0001 per share (the “ common stock ”), had traded at a value below the minimum $50,000,000 “Market Value of Listed Securities” (“ MVLS ”) requirement set forth in Nasdaq Listing Rule 5450(b)(2)(A), which is required for continued listing of the Company’s common stock on Nasdaq.”

Zoomcar Holdings, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“March 31, 2023, Innovative International Acquisition Corp. (the “Company”) received a written notice (the “Letter”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company was not in compliance with Listing Rule 5450(b)(2)(A), requiring the Company to maintain a Market Value of Listed Securities (“MVLS”) of $50,000,000 for the continued listing of its securities on The Nasdaq Global Market. The Letter is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s s”

InterPrivate IV InfraTech Partners Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

“April 3, 2023, InterPrivate IV InfraTech Partners Inc. (the “Company”) received a letter from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the Company’s minimum Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “Market Value Standard”). The notice has no immediate effect on the listing of the Company’s common stock, and the Company’s common stock contin”

Marblegate Acquisition Corp. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“March 31, 2023, Marblegate Acquisition Corp. (the “Company”) received a deficiency notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is no longer in compliance with the minimum Market Value of Listed Securities (“MVLS”) of $50 million for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Requirement”). This notification has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Global Market and the Company’s Class A common”

Social Leverage Acquisition Corp I received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“April 3, 2023, Social Leverage Acquisition Corp I, a Delaware company (the “Company”) received a letter (the “Letter”) from the staff at The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the 30 consecutive trading days prior to the date of the Letter, the Company’s common stock had traded at a value below the minimum $50,000,000 “Market Value of Listed Securities” (“MVLS”) requirement set forth in Nasdaq Listing Rule 5450(b)(2)(A), which is required for continued listing of the Company’s common stock on The Nasdaq Global Market. The Letter is only a notification of deficie”

Evo Acquisition Corp received a nasdaq deficiency notice notice regarding shareholders (rules 5550(a)(4)).

“April 5, 2023, the Company received another letter (the “Public Float Notice”) from Nasdaq notifying the Company that the Company no longer meets the minimum 500,000 publicly held shares required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(4) (the “Public Float Standard”). The Public Float Notice states that the Company has until May 22, 2023 to provide Nasdaq with a specific plan to achieve and sustain compliance with all The Nasdaq Capital Market listing requirements, including the time frame for completion of this plan. If Nasdaq does not accep”

Evo Acquisition Corp received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“April 3, 2023, Evo Acquisition Corp. (the “Company”) received a letter (the “MVLS Notice”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the Company’s Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “Market Value Standard”). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has 180 calendar days, or until October 2, 2023, to regain”

System1, Inc. received a nyse deficiency notice notice regarding late filing (rules 802.01E).

“April 3, 2023, System1, Inc. (the “Company”) received a notice letter (the “Notice”) from the NYSE Regulation Department (the “Staff”) of the New York Stock Exchange (“NYSE”) notifying the Company that, based upon the Company’s failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “Annual Report”), it was not in compliance with the NYSE’s continued listing requirements. Specifically, Section 802.01E of the NYSE Listed Company Manual provides that an NYSE-listed company is not in compliance if it does not timely file its annual and interim report”

Crown Electrokinetics Corp. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“April 3, 2023, the Company received an additional notice from the Staff indicating that the Company’s non-compliance with the $2,500,000 minimum stockholders’ equity requirement as of December 31, 2023, and its alternatives, as set forth in Nasdaq Listing Rule 5550(b)(1), could serve as an additional basis for delisting and, accordingly, the Company must address the equity deficiency at its upcoming hearing before the Panel. The Company is diligently working to evidence compliance with all applicable Nasdaq listing criteria; however, there can be no assurance that the Panel will grant the Comp”

Equillium, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5450(a)(1)).

“April 5, 2023, Equillium, Inc. (the “Company”) received a notice from The Nasdaq Stock Market (“Nasdaq”) that the Company is not in compliance with Nasdaq’s Listing Rule 5450(a)(1), as the minimum bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days. The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Global Market. The Company has 180 days, or until October 2, 2023, to regain compliance with the minimum bid price requirement. To regain compliance, the minimum bid pric”

Kaleyra, Inc. received a nyse deficiency notice notice regarding market value (rules 802.01B).

“stockholders’ equity was less than $50 million (the “Market Capitalization Deficiency”). As of March 31, 2023, the 30 trading-day average market capitalization was approximately $31.5 million, and its last reported stockholders’ equity was $42.2 million as of December 31, 2022. In accordance with applicable NYSE procedures, the Company has 45 days from receipt of the”

9 METERS BIOPHARMA, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“March 31, 2023, the Company received a letter from Nasdaq indicating that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Stock Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. In its annual report on Form 10-K for the period ended December 31, 2023, the Company reported stockholders’ equity of $2,400,543, and, as a result, does not currently satisfy Listing Rule 5550(b)(1). Nasdaq’s letter has no immediate impact on the listing of the Company’s common stock, which will continue to be listed and”